Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon’s One Medical rollout of GLP-1 weight-loss drugs (oral and injectable) creates a major new competitor for Hims & Hers, threatening Hims’s pricing, membership and delivery advantages. Amazon offers oral GLP-1s and injectables with cash prices as low as $149–$299/month, faster same-day delivery in thousands of cities and a low add-on membership cost for Prime members, undercutting Hims’s higher membership fees and slower delivery. The move knocked HIMS shares lower and raises the risk to Hims’s growth trajectory despite its 2.5M subscribers and strong 2025 revenue growth. Analysts remain mixed on Hims (MarketBeat consensus price target ~$32.53), and it will likely take several quarters to quantify Amazon’s market impact. Overall, the development is bullish for Amazon’s consumer-health positioning and bearish to mixed for Hims’s competitive outlook and near-term stock performance.